Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 27
Vaccines Against Malaria: Hope in a Gathering Storm Appendix Workshop Agenda INSTITUTE OF MEDICINE National Academy of Sciences Board on International Health Board on Health Promotion and Disease Prevention Workshop on Malaria Vaccines 19–20 October 1995 Cecil and Ida Green Building, Room 104 2001 Wisconsin Avenue, N.W. Washington, DC 20007 (202) 334-3904 AGENDA 19 October 1995 8:30 a.m.–8:45 a.m. Welcome and Introductions Philip Russell, Chair, IOM Committee on Malaria Vaccines 8:45 a.m.–10:45 a.m. SESSION I: SETTING THE STAGE (8:45 a.m.–9:15 a.m.) Malaria: The Deteriorating Situation Donald Krogstad, Tulane University School of Public Health and Tropical Medicine, USA (9:15 a.m.–9:45 a.m.) The Promise of Malaria Vaccines Jerald Sadoff, Merck Research Laboratories, USA
OCR for page 28
Vaccines Against Malaria: Hope in a Gathering Storm (9:45 a.m.–10:05 a.m.) Malaria Vaccines in the Field: A Perspective from the Africa Malaria Vaccine Testing Network Wenceslaus Kilama, The African Malaria Vaccine Testing Network, Tanzania (10:05 a.m.–10:30 a.m.) Discussion Moderator: Philip Russell 10:30 a.m.–11:00 a.m. Break 11:00 a.m.–12:00 p.m. SESSION II: MALARIA AS A PARADIGM Stephen Hoffman, Naval Medical Research Institute, USA (11:40 a.m.–12:00 p.m.) Discussion Moderator: Louis Miller, National Institutes of Health, USA 12:00 p.m.–1:00 p.m. Lunch 1:00 p.m.–3:30 p.m. SESSION III: CURRENT APPROACHES TO MALARIA VACCINE DEVELOPMENT (1:00 p.m.–1:25 p.m.) Preerythrocytic Vaccines Ruth Nussenzweig, New York University Medical Center, USA (5 min.) Questions (1:30 p.m.–1:55 p.m.) Erythrocytic Vaccines Graham Brown, The Walter and Eliza Hall Institute of Medical Research, Australia (5 min.) Questions (2:00 p.m.–2:25 p.m.) Transmission Blocking Vaccines David Kaslow, National Institutes of Health, USA (5 min.) Questions (2:30 p.m.–3:30 p.m.) Discussion: Potential Immunologic Obstacles toDevelopment of an Optimal Multi-Immune Response, Multi-Stage Malaria Vaccine Moderator: W. R. Ballou, Walter Reed Army Institute of Research, USA 3:30 p.m.–4:00 p.m. Break
OCR for page 29
Vaccines Against Malaria: Hope in a Gathering Storm 4:00 p.m.–5:30 p.m. SESSION IV: ROUNDTABLE ON U.S. FEDERAL MALARIA VACCINE ACTIVITIES Summary of Agency Activities 20 October 1995 (4:00 p.m.–4:15 p.m.) Public Health Service Daniel Colley, Centers for Disease Control and Prevention (4:15 p.m.–4:30 p.m.) Department of Defense William Bancroft, U.S. Army Medical Research and Materiel Command (4:30 p.m.–4:45 p.m.) U.S. Agency for InternationalDevelopment Carter Diggs, USAID (4:45 p.m.–5:00 p.m.) Federal Malaria Vaccine Coordinating Committee Lee Hall, National Institutes of Health (5:00 p.m.–5:30 p.m.) Roundtable Discussion Moderator: Lee Hall 5:30 p.m. Reception (North Prefunction Area, directly outside meeting room) 8:30 a.m.–10:15 a.m. SESSION V: ROUNDTABLE ON INDUSTRIAL SECTOR ACTIVITIES (8:30 a.m.–9:00 a.m.) Malaria Vaccine Development: A Perspective from Industry Russell Howard, Glaxo-Wellcome (9:00 a.m.–9:35 a.m.) The following participants may wish to present for 5 min. each: Ian Bathurst, LXR Biotechnology W. Neal Burnette, Molecular Pharmaceutics Corporation Kenneth Guito, Connaught Laboratories Maurice Hilleman, The Merck Institute Adeoye Olukotun, Bristol-Myers Squibb Company John Tine, Virogenetics Corporation
OCR for page 30
Vaccines Against Malaria: Hope in a Gathering Storm (9:35 a.m.–10:15 a.m.) Roundtable Discussion Moderator: Russell Howard 10:15 a.m.–10:45 a.m. Break 10:45 a.m.–12:15 a.m. SESSION VI: ROUNDTABLE ON INTERNATIONAL COLLABORATION (10:45 a.m.–11:00 a.m.) Overview of Global Malaria Vaccine Activities Howard Engers, WHO Special Programme for Research and Training in Tropical Diseases, Switzerland (11:00 a.m.–11:15 a.m.) DANIDA and Commission of European Communities Palle Jakobsen, Denmark (11:15 a.m.–11:25 a.m.) African Malaria Vaccine Testing Network Wenceslaus Kilama, Tanzania (11:25 a.m.–11:35 a.m.) Walter and Eliza Hall Institute of Medical Research Graham Brown, Australia (11:35 a.m.–11:45 a.m.) Medical Research Council Michael Davies, Great Britain (11:45 a.m.–12:15 p.m.) Roundtable Discussion Moderator: Howard Engers (session will include participants from the Roundtable on U.S. Federal Malaria Vaccine Activities) 12:15 p.m.–1:00 p.m. SESSION VII: SUMMARY AND DISCUSSION OF FINDINGS, CONCLUSIONS, AND RECOMMENDATIONS Philip Russell, IOM Committee Chair 1:00 p.m. Workshop Adjournment 1:30 p.m.–5:00 p.m. EXECUTIVE SESSION Workshop Committee on Malaria Vaccines
Representative terms from entire chapter: